Novel actions of inverse agonists on 5-HT2C receptor systems.

In cell systems where ligand-independent receptor activity is optimized (such as when receptors are overexpressed or mutated), acute treatment with inverse agonists reduces basal effector activity whereas prolonged exposure leads to sensitization of receptor systems and receptor up-regulation. Few studies, however, have reported effects of inverse agonists in systems where nonmutated receptors are expressed at relatively low density. Here, we investigated the effects of inverse agonists at human serotonin (5-HT)2C receptors expressed stably in Chinese hamster ovary cells ( approximately 250 fmol/mg protein). In these cells, there is no receptor reserve for 5-HT and 5-HT2C inverse agonists did not reduce basal inositol phosphate (IP) accumulation nor arachidonic acid (AA) release but behaved as simple competitive antagonists, suggesting that these receptors are not overexpressed. Prolonged treatment (24 h) with inverse agonists enhanced selectively 5-HT2C-mediated IP accumulation but not AA release. The enhancing effect occurred within 4 h of treatment, reversed within 3 to 4 h (after 24-h treatment), and could be blocked with neutral antagonists or weak positive agonists. The enhanced responsiveness was not due to receptor up-regulation but may involve changes in the expression of the G protein, Galphaq/11 and possibly Galpha12 and Galpha13. Interestingly, 24-h exposure to inverse agonists acting at 5-HT2C receptors also selectively enhanced IP accumulation, but not AA release, elicited by activation of endogenous purinergic receptors. These data suggest that actions of inverse agonists may be mediated through effects on receptor systems that are not direct targets for these drugs.

[1]  N. Dhanasekaran,et al.  Ras-dependent Signaling by the GTPase-deficient Mutant of Gα12 * , 1997, The Journal of Biological Chemistry.

[2]  M. Lohse,et al.  Molecular mechanisms of membrane receptor desensitization. , 1993, Biochimica et biophysica acta.

[3]  G. Milligan,et al.  Up‐regulation of a constitutively active form of the β 2‐adrenoceptor by sustained treatment with inverse agonists but not antagonists , 1996, FEBS letters.

[4]  B. H. Shah,et al.  The gonadotrophin-releasing hormone receptor of alpha T3-1 pituitary cells regulates cellular levels of both of the phosphoinositidase C-linked G proteins, Gq alpha and G11 alpha, equally. , 1994, Molecular pharmacology.

[5]  Christopher J. Evans,et al.  Morphine Activates Opioid Receptors without Causing Their Rapid Internalization* , 1996, The Journal of Biological Chemistry.

[6]  P. Casey,et al.  Signalling functions and biochemical properties of pertussis toxin-resistant G-proteins. , 1997, The Biochemical journal.

[7]  R. Lefkowitz,et al.  A constitutively active mutant beta 2-adrenergic receptor is constitutively desensitized and phosphorylated. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[8]  L. Miller,et al.  Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor. , 1997, Molecular pharmacology.

[9]  R. McKay,et al.  5-Hydroxytryptamine type 2A receptors regulate cyclic AMP accumulation in a neuronal cell line by protein kinase C-dependent and calcium/calmodulin-dependent mechanisms. , 1994, Molecular pharmacology.

[10]  P. Leff,et al.  A three-state receptor model of agonist action. , 1997, Trends in pharmacological sciences.

[11]  G. Milligan,et al.  Inverse agonist-induced up-regulation of the human beta2-adrenoceptor in transfected neuroblastoma X glioma hybrid cells. , 1996, Molecular pharmacology.

[12]  G. Milligan,et al.  Inverse agonism: pharmacological curiosity or potential therapeutic strategy? , 1995, Trends in pharmacological sciences.

[13]  R. Lefkowitz,et al.  Ligand-induced overexpression of a constitutively active beta2-adrenergic receptor: pharmacological creation of a phenotype in transgenic mice. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[14]  D Rodbard,et al.  Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. , 1992, Molecular pharmacology.

[15]  M. Kaufman,et al.  Serotonin 5‐HT2C Receptor Stimulates Cyclic GMP Formation in Choroid Plexus , 1995, Journal of neurochemistry.

[16]  J. Black,et al.  Inverse agonists exposed , 1995, Nature.

[17]  P. Leff,et al.  Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. , 1998, Molecular pharmacology.

[18]  P. Leff,et al.  The two-state model of receptor activation. , 1995, Trends in pharmacological sciences.

[19]  R. Lefkowitz,et al.  A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. , 1993, The Journal of biological chemistry.

[20]  P. Chidiac,et al.  Agonist-induced modulation of inverse agonist efficacy at the beta 2-adrenergic receptor. , 1996, Molecular pharmacology.

[21]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[22]  G. Milligan,et al.  Up-regulation of the levels of expression and function of a constitutively active mutant of the hamster alpha1B-adrenoceptor by ligands that act as inverse agonists. , 1997, The Biochemical journal.

[23]  E. sanders-Bush,et al.  5-hydroxytryptamine1C receptor density and mRNA levels in choroid plexus epithelial cells after treatment with mianserin and (-)-1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane. , 1993, Molecular pharmacology.

[24]  M. Simon,et al.  Organization of transmembrane signalling by heterotrimeric G proteins. , 1996, Cancer surveys.

[25]  E. sanders-Bush,et al.  Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands. , 1994, The Journal of biological chemistry.

[26]  P. Chidiac,et al.  Serotonergic antagonists differentially inhibit spontaneous activity and decrease ligand binding capacity of the rat 5-hydroxytryptamine type 2C receptor in Sf9 cells. , 1995, Molecular pharmacology.

[27]  S. Rhee,et al.  Regulation of Phosphoinositide-specific Phospholipase C Isozymes* , 1997, The Journal of Biological Chemistry.

[28]  R. Leurs,et al.  Inverse agonism of histamine H2 antagonist accounts for upregulation of spontaneously active histamine H2 receptors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[29]  G. Milligan,et al.  Inverse agonism and the regulation of receptor number. , 1997, Trends in pharmacological sciences.

[30]  R. Graham,et al.  Constitutive activation of a single effector pathway: evidence for multiple activation states of a G protein-coupled receptor. , 1996, Molecular pharmacology.

[31]  M. Pranzatelli,et al.  Novel regulation of 5-HT1C receptors: down-regulation induced both by 5-HT1C/2 receptor agonists and antagonists. , 1993, European journal of pharmacology.

[32]  J. Axelrod,et al.  Serotonin stimulates phospholipase A2 and the release of arachidonic acid in hippocampal neurons by a type 2 serotonin receptor that is independent of inositolphospholipid hydrolysis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[33]  M. Breeding,et al.  Putative selective 5-HT-2 antagonists block serotonin 5-HT-1c receptors in the choroid plexus. , 1988, The Journal of pharmacology and experimental therapeutics.

[34]  A. Saltzman,et al.  Signal transduction differences between 5-hydroxytryptamine type 2A and type 2C receptor systems. , 1994, Molecular pharmacology.

[35]  Brian K. Kobilka,et al.  Structural Instability of a Constitutively Active G Protein-coupled Receptor , 1997, The Journal of Biological Chemistry.

[36]  M. Zuscik,et al.  Identification of a Conserved Switch Residue Responsible for Selective Constitutive Activation of the β2-Adrenergic Receptor* , 1998, The Journal of Biological Chemistry.

[37]  S. Cockcroft,et al.  Inositol-lipid-specific phospholipase C isoenzymes and their differential regulation by receptors. , 1992, The Biochemical journal.

[38]  T. Kenakin.  The classification of seven transmembrane receptors in recombinant expression systems. , 1996, Pharmacological reviews.

[39]  S. Maayani,et al.  5-hydroxytryptamine2C receptor activation inhibits 5-hydroxytryptamine1B-like receptor function via arachidonic acid metabolism. , 1996, Molecular pharmacology.

[40]  I. Forbes,et al.  In vitro and in vivo profile of SB 206553, a potent 5‐HT2C/5‐HT2B receptor antagonist with anxiolytic‐like properties , 1996, British journal of pharmacology.